Robotic Ablatherm HIFU’s Importance in Prostate Cancer Surgeries Featured in Major Conferences

The Ablatherm-HIFU devices and the upgraded lithotripsy products were featured at two international conferences that were held recently. A total of eight presentations at the 29th World Congress of Endurology and SWL (WCE) held from 30 November to 3 December in Japan supported the usage of Ablatherm-HIFU in treating localised prostate cancer.

At the First Montreal Conference of Focal Therapy for Prostate Cancer that was held at Montreal on 2 December, EDAP had presented the new positioning for robotic the Ablatherm-HIFU as a ‘must have’ component to prostate cancer surgery.

The CEO of EDAP explained that at WCE, they had seen a shift in the urological community in the way prostate cancer was being treated. The treatment methods were more focussed on providing customised treatment based on the patient’s potency and continence. He added that the Albatherm-HIFU is being considered as an important part of focal therapy treatment approach for treating prostate cancer. At the WCE, EDAP had demonstrated the Albatherm-HIFU along with lithotripsy devices such as Sonolithi-sys and i-move. At the Montreal Conference urologists expressed their interest in using the Albatherm for providing localised prostate cancer treatment for young patients. The concept of focal therapy will provide the patients better control of their disease and means of preserving their quality of life.